Incyte stock reports 38 percent revenue growth as shares trade at USD 123.47

Published on 09/25/2026 at 15:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 2026 Opzelura sales reached USD 449.7 million, up 173 percent year over year. A September 20, 2026 partnership broadens Australian distribution.

Fotorealistisches Biopharma-Labor mit Wissenschaftlern und bunten Zellkulturen — Incyte Biopharma-Forschungslabor zeigt Wissenschaftler an Mikroskopen, Petrischalen und Zentrifugen, ISIN US45337C1027 Biotech, Illustration mit AI erstellt.

Incyte (ISIN US45337C1027) stock reports 38 percent revenue growth as shares trade at USD 123.47 on Nasdaq on September 25, 2026 at 9:57 a.m. ET. The latest commercial development is an expanded Opzelura partnership for Australia announced on September 20, 2026.

Revenue growth sets the baseline

According to Yahoo Finance, Incyte generated USD 1.67 billion in Q2 2026 revenue, up 38 percent from the year-ago quarter and above the USD 1.46 billion consensus estimate.

The same Q2 2026 report showed adjusted earnings per share of USD 3.09 versus USD 2.00 consensus. Opzelura sales reached USD 449.7 million, up 173 percent year over year, although the result included a USD 246 million non-cash benefit from reversed accruals.

Australia adds a commercial route

PR Newswire reported on September 20, 2026 that Specialised Therapeutics expanded its existing partnership with Incyte to commercialize, register and distribute ruxolitinib cream in Australia.

Incyte will continue development and manufacturing, while Specialised Therapeutics handles regulatory submissions, medical affairs, marketing and distribution. The release also said more than one million patients globally had been treated with Opzelura.

Stock sits below yearly peak

Incyte stock was trading at USD 123.47 on Nasdaq at 9:57 a.m. ET on September 25, 2026, down USD 0.97 or 0.78 percent from the prior close of USD 124.44. The session range was USD 123.09 to USD 125.99, and market capitalization stood at USD 25,026,077,210.

The USD 123.47 price was 6.89 percent below the 52-week high of USD 132.60 and above the 52-week low of USD 81.78. For investors, the central contrast is clear: operating growth remains strong in the latest reported quarter, while the share price is still below its yearly peak.

Trading snapshot keeps the comparison clear

At 9:57 a.m. ET on September 25, 2026, Incyte stock stood at USD 123.47 on Nasdaq, with volume of 83,144 shares. The dated market value places the stock below its 52-week high while the Q2 2026 figures provide the more substantial operating comparison.